Vilazodone

Introduction Overview

Generic Name

vilazodone

Brand Name

Viibryd, Viibryd Starter

Dosage Form

oral tablet (10 mg; 20 mg; 40 mg)

Drug Class

Miscellaneous antidepressants

Pharmacokinetics

Vilazodone pharmacokinetics involve multiple processes critical to its clinical efficacy and safety.

Absorption: Vilazodone is well absorbed orally, demonstrating improved bioavailability when taken with food. Peak plasma concentrations (Cmax) are typically reached within 3–5 hours post-dose. The presence of food significantly enhances absorption, with studies showing increased systemic exposure, making it imperative to administer vilazodone with meals to optimize therapeutic effect. The oral bioavailability is moderate due to first-pass metabolism.

Distribution: Vilazodone is highly protein bound (~96–99%) in plasma, primarily to albumin, limiting its free circulating concentration. The volume of distribution (Vd) is relatively extensive, indicating significant tissue distribution. The drug's lipophilicity facilitates penetration across the blood-brain barrier, allowing effective central nervous system (CNS) activity necessary for antidepressant effects.

Metabolism: Extensive hepatic metabolism is involved, primarily mediated through cytochrome P450 isoenzyme CYP3A4, with minor contributions from CYP2C19 and CYP2D6 pathways. Vilazodone undergoes oxidative metabolism producing multiple metabolites, most of which are pharmacologically inactive. No active metabolites with significant antidepressant activity have been identified, and metabolic pathways influence potential drug-drug interactions.

Elimination: The elimination half-life ranges from approximately 25 to 33 hours, supporting once-daily dosing. Vilazodone and its metabolites are primarily excreted via feces (~70%) and urine (~20%), consistent with hepatobiliary clearance. Renal clearance is minimal; therefore, mild to moderate renal impairment does not significantly affect elimination. Hepatic impairment may alter metabolism, necessitating careful clinical monitoring. These pharmacokinetic characteristics support vilazodone’s dosing strategies and inform clinical considerations regarding interactions and adverse effect profiles.

Dosage Forms

Available Dosage Forms: Vilazodone is commercially available as oral tablets in three strengths: 10 mg, 20 mg, and 40 mg. These tablets are formulated for oral administration and designed to be taken with food to enhance absorption and tolerability.

Dosages for Adults and Adolescents: The recommended initial dose for adults with major depressive disorder (MDD) is 10 mg once daily for the first 7 days. This is followed by an increase to 20 mg once daily for an additional 7 days. The maintenance dose is then 40 mg orally once daily. Dosage adjustments should be guided by clinical response and tolerability. Treatment with vilazodone in patients under 18 years of age is not approved due to insufficient safety and efficacy data.

Specific Patient Populations: Dose modifications in patients with hepatic or renal impairment have not been extensively studied; however, given its metabolism, caution is warranted in severe hepatic impairment. Vilazodone is not established as safe in pregnancy or breastfeeding; clinicians should weigh benefits against potential risks and monitor accordingly. There is no specific dosing guideline alteration required in elderly patients, but careful clinical observation is advised. The oral tablet must always be taken with food to improve bioavailability and reduce the incidence of gastrointestinal adverse effects.

Mechanism Of Action

Vilazodone exhibits a unique mechanism of antidepressant action characterized by its dual activity as a selective serotonin reuptake inhibitor (SSRI) and a partial agonist at the serotonin 5-HT1A receptor. This dual pharmacological profile distinguishes vilazodone from conventional SSRIs, which primarily function by inhibiting serotonin reuptake.

At the molecular level, vilazodone binds to the serotonin transporter (SERT), inhibiting the reabsorption of serotonin (5-HT) from the synaptic cleft back into presynaptic neurons. This inhibition results in increased synaptic serotonin levels, thereby enhancing serotonergic neurotransmission associated with mood improvement and antidepressant effects. Concurrently, vilazodone's partial agonist activity at the 5-HT1A receptor modulates serotonergic signaling, which may contribute to anxiolytic properties and potentially faster onset of antidepressant action.

Cellular downstream pathways affected by 5-HT1A activation include modulation of cyclic AMP (cAMP) and protein kinase A (PKA) signaling, influencing gene expression and neuronal plasticity. This receptor interaction can also attenuate serotonin autoreceptor-mediated feedback inhibition, potentially mitigating some common SSRI side effects and tolerance phenomena.

Clinical studies indicate that the combined SSRI and 5-HT1A partial agonist activities may offer advantages including improved efficacy in major depressive disorder and a favorable tolerability profile. Comparative research suggests that vilazodone may have lower incidence of sexual dysfunction and weight gain versus classical SSRIs, although direct head-to-head trials are limited. The distinct pharmacodynamic properties align with evidence pointing toward enhanced serotonergic modulation without significant dopaminergic or noradrenergic effects.

Pharmacological Actions

Selective inhibition of serotonin reuptake via serotonin transporter blockade.
Partial agonism at the serotonin 5-HT1A receptor, modulating serotonergic neurotransmission.
Enhancement of synaptic serotonin concentration leading to mood elevation.
Modulation of neuronal signaling pathways associated with mood and anxiety regulation.
Anxiolytic action attributed to 5-HT1A receptor partial agonism.
Lack of significant activity on dopaminergic or noradrenergic systems reduces off-target effects.
Displays antidepressant properties effective in major depressive disorder.
Lower propensity for sexual dysfunction symptoms compared to traditional SSRIs.
Potential to produce faster antidepressant response due to dual mechanism.
Minimal sedative effects, contributing to better tolerability.
Negligible impact on histaminergic or cholinergic receptors, reducing certain side effects.
Influences downstream intracellular signaling cascades related to neuroplasticity.
Does not significantly inhibit monoamine oxidase enzymes.
Lacks substantial effects on cardiovascular conduction and cardiac ion channels.
Exhibits a low potential for drug dependency or abuse.

Therapeutic Or Clinical Uses

Treatment of major depressive disorder (MDD) in adults.
Alleviation of depressive symptoms with both emotional and somatic components.
Management of anxiety features within depressive episodes.
Alternative therapy for patients intolerant to conventional SSRIs or SNRIs.
Adjunctive treatment to psychotherapy in depression.
Potential off-label use in generalized anxiety disorder (though not FDA approved).
Used in patients who require antidepressants with a lower risk of sexual side effects.
Treatment choice for MDD where rapid onset of action is desirable.
Employed in cases requiring drugs with a favorable safety and side effect profile.
Option in patients where weight neutrality is clinically important.
Salvage therapy for treatment-resistant depression in select cases.
Considered when polypharmacy risks require drugs with minimal interactions.
Used when clinicians aim to minimize sedation and cognitive impairment.
May be used in patients with comorbid depressive and anxiety disorders.
Selected for patients with prior adverse reactions to tricyclic or MAOI antidepressants.

Side Or Adverse Effects

Nausea and vomiting, commonly reported especially during initiation.
Diarrhea, which may be transient but sometimes requires management.
Insomnia or other sleep disturbances including difficulty falling and staying asleep.
Potential for headache related to serotonergic activity.
Dizziness or lightheadedness especially when rising from sitting or lying positions.
Sexual dysfunction including decreased libido, anorgasmia, or erectile difficulties.
Risk of bleeding or bruising, particularly when combined with NSAIDs or anticoagulants.
Rare but serious risk of seizures, predominantly in predisposed individuals.
Visual disturbances such as blurred or tunnel vision reported infrequently.
Serotonin syndrome risk when combined with other serotonergic agents.
Hyponatremia presenting with confusion, headache, or coordination loss, especially in elderly.
Possible weight changes, typically weight neutral but isolated weight loss reported.
Mood instability including irritability, agitation, or suicidality, primarily in young adults.
Withdrawal symptoms on abrupt discontinuation, including agitation and electric shock sensations.
Allergic reactions such as skin rash, urticaria, or angioedema, although rare.

Precautions

Avoid use in combination with monoamine oxidase inhibitors (MAOIs) within 14 days before or after treatment.
Monitor for worsening depression, suicidal ideation especially in young adults under 25.
Exercise caution in patients with history of seizures or epilepsy.
Use carefully in patients with bipolar disorder to avoid precipitating mania or hypomania.
Avoid abrupt discontinuation to minimize risk of withdrawal symptoms.
Take vilazodone with food to improve absorption and reduce gastrointestinal adverse effects.
Use cautiously in patients with liver impairment; clinical monitoring advised.
Beware of potential bleeding risk when coadministered with anticoagulants, NSAIDs or antiplatelet agents.
Advise patients about possible sexual side effects and discuss management strategies.
Avoid alcohol use during treatment to prevent additive CNS depression.
Monitor electrolyte levels in elderly patients or those taking diuretics due to hyponatremia risk.
Report any vision changes promptly owing to possible ocular adverse effects.
Educate patients about serotonin syndrome symptoms and need for immediate medical attention.
Regularly assess mental status and mood, especially during dose initiation and adjustments.
Advise women of childbearing potential about pregnancy registry enrollment and risks.

Warnings

May increase risk of suicidal thoughts and behaviors in children, adolescents, and young adults.
Not approved for use in patients younger than 18 years.
Do not discontinue vilazodone suddenly—may cause withdrawal symptoms including agitation and 'electric shock' sensations.
Risk of serotonin syndrome especially when combined with other serotonergic drugs.
Potential serious allergic reactions including anaphylaxis or angioedema.
Use with caution in patients with bleeding disorders or those on concomitant anticoagulant therapy.
Avoid concomitant use with monoamine oxidase inhibitors to prevent hypertensive crisis.
Pregnancy exposure may harm the fetus; however, abrupt discontinuation may pose maternal risks.
Avoid hazardous activities until drug's effects on alertness and reaction time are known.
Patients should be monitored for behavioral changes, especially emergence of anxiety or mania.
Monitor for electrolyte imbalances, particularly hyponatremia in vulnerable populations.
Concomitant use with NSAIDs, aspirin, or other platelet aggregation inhibitors increases bleeding risk.
Fatal overdose is possible; keep out of reach of children and avoid accidental ingestion.
Clinical surveillance is essential during dose titration and when combined with CNS depressants.
Inform patients about potential vision abnormalities requiring immediate assessment.

Contraindication

Concurrent or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs).
Known hypersensitivity to vilazodone or any of its formulation components.
History of allergic reactions to vilazodone manifesting as rash, urticaria, or angioedema.
Use in pediatric patients under 18 years of age due to safety and efficacy concerns.
Concomitant use with other serotonergic drugs that have not been medically supervised.
Co-administration with methylene blue injection or intravenous linezolid due to serotonin syndrome risk.
Patients with untreated narrow-angle glaucoma due to risk of increased intraocular pressure.
Active seizure disorder uncontrolled by medication without specialist consultation.
Known bleeding disorders with elevated risk that cannot be monitored.
Severe hepatic impairment lacking safety data.
Pregnancy and breastfeeding where risks outweigh benefits without consultation.
Patients exhibiting manic episodes or bipolar mania not adequately stabilized.
Recent history of drug addiction or suicidal behavior without psychiatric stabilization.
Use alongside St. John's Wort or other herbal serotonergic supplements uncontrolled by physician.
Simultaneous use with medications known for severe interactions—requires specialist oversight.

Drug Interactions

Monoamine oxidase inhibitors (MAOIs): concomitant use or recent use (<14 days) contraindicated due to hypertensive crisis risk.
Other serotonergic agents (SSRIs, SNRIs, triptans, tramadol, St. John's Wort): increased risk of serotonin syndrome.
CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase vilazodone plasma levels, enhancing side effects.
CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce vilazodone efficacy by lowering plasma concentrations.
Warfarin and other anticoagulants: increased bleeding risk when combined with vilazodone.
NSAIDs and antiplatelet agents: additive bleeding tendency, especially gastrointestinal.
Central nervous system depressants (benzodiazepines, opioids, muscle relaxants): may potentiate sedation and impairment.
Phenytoin and mephenytoin: potential interaction influencing metabolism and plasma concentrations.
Diuretics: may exacerbate electrolyte disturbances, especially hyponatremia when combined with vilazodone.
Migraine medications (sumatriptan, rizatriptan): increased serotonin syndrome risk.
Triptans and linezolid: risk of additive serotonergic effects and hypertensive crises.
Herbal supplements like St. John's Wort: unpredictable interaction increasing serotonergic activity.
CYP2C19 and CYP2D6 inhibitors may also affect metabolism, though to lesser extent than CYP3A4 modulators.
Opioid analgesics may pose increased sedation risk when co-administered.
Alcohol may exacerbate CNS depressant effects and increase side effects.

Preparations Of The Drug

Oral tablet formulation containing vilazodone at strengths of 10 mg, 20 mg, and 40 mg.
Tablets designed for oral administration with food to ensure adequate absorption.
Film-coated tablets to enhance patient compliance and ease of swallowing.
Available as brand-name products such as Viibryd and Viibryd Starter for dose titration.
Packaging designed to protect from moisture and heat, maintaining drug stability.
Prescribed specifically for treatment of major depressive disorder in adults.
Identified by distinct imprint codes and coloring for differentiation of dosage strengths.
No generic formulations currently widely available; branded formulations have established bioequivalence data.
Not formulated for parenteral or non-oral administration routes.
Supplied with patient information leaflets emphasizing dosing with food and warnings.
Formulation free of significant allergenic excipients to minimize hypersensitivity risk.
Manufactured under Good Manufacturing Practices (GMP) adhering to FDA standards.
Stability maintained at room temperature, avoiding extremes of moisture and heat.
Dispensed only by prescription with careful patient counseling recommended.
Storage and disposal instructions emphasize safety to prevent accidental ingestion.